Navigo Proteins has appointed Dr Florian Settele as Managing Director of Navigo Pure, placing an experienced internal leader at the head of its affinity chromatography and downstream bioprocessing business.
Settele takes on the role with immediate effect. Navigo Pure is focused on affinity chromatography products and custom purification solutions for biopharmaceutical manufacturing, including catalogue and tailored products designed to support robust, scalable, and cost-effective downstream processing.
Settele has been part of Navigo Proteins for 15 years and has held roles across research and development, external collaborations, commercial alliances, and business unit leadership. He previously worked at the German Cancer Research Center and holds a PhD in Cell and Molecular Biology from the University of Heidelberg, as well as an MBA from HHL Leipzig Graduate School of Management.
His appointment marks the next stage in Navigo Pure’s development as the company builds its pipeline of affinity chromatography products. The business is part of Navigo Proteins’ wider structure, which includes Navigo Pure and Navigo Precision as core subsidiaries around protein engineering, purification, targeted therapies, and diagnostics.
“It is a privilege to take on this new responsibility as Managing Director of Navigo Pure,” Settele said. “Having been part of the company’s journey for 15 years, I look forward to building on this strong foundation together with our team and further expanding Navigo Pure’s position as an innovative partner in downstream bioprocessing.”
Dr Henning Afflerbach, CEO of Navigo Proteins, said Settele’s appointment was “a natural next step for Navigo Pure and for Navigo Proteins.”
Downstream processing is becoming one of the most demanding constraint points in advanced medicines manufacturing. Biopharmaceutical pipelines are increasingly diverse, spanning monoclonal antibodies, antibody-drug conjugates, recombinant proteins, enzymes, peptides, viral vectors, vaccines, radiopharmaceutical approaches, and other complex biologics. Each product type can create different purification challenges.
Navigo Pure positions its Precision Capturing platform around custom-engineered affinity ligands and one-step purification for complex biologics. The company says the technology is designed to replace more complex purification processes with high-performance chromatography steps using purpose-built ligands. The approach addresses a recurring bioprocessing problem: upstream productivity has improved, while downstream purification can still limit yield, cost, scalability, and speed to market.
Affinity chromatography remains central to biologics manufacturing because it allows highly selective capture of target molecules. Protein A has long been established in monoclonal antibody production, but newer biologics often lack standardised purification routes. Custom affinity ligands can create more direct capture strategies, although development must also satisfy manufacturing, regulatory, leachables, cleaning, lifetime, and GMP supply requirements.
Europe’s advanced medicines manufacturing base is also strengthening around specialised capabilities. Sandoz’s investment in Slovenian biosimilar development capacity showed how complex biologics are driving investment in technical infrastructure. Navigo Pure sits further upstream in the enabling technology chain, where purification products and process development influence whether medicines can be manufactured efficiently.
The commercial pressure is substantial. Biopharmaceutical companies want purification routes that can move from development to clinical and commercial manufacturing without repeated redesign. A process that works at small scale but becomes slow, expensive, or low-yield in GMP production can delay programmes and add cost. Downstream processing is also sensitive to product quality attributes, impurities, aggregation, host cell proteins, DNA, resin performance, and process robustness.
Custom chromatography products can address those issues, although they require close collaboration between ligand developers, resin suppliers, process engineers, analytical teams, and manufacturers. Leadership in this segment depends on scientific depth and a clear understanding of customer manufacturing constraints. Settele’s background across R&D, collaborations, commercial alliances, and business unit leadership gives the appointment an operational logic beyond succession planning.
The broader trend is toward platformisation where possible and customisation where necessary. Manufacturers want repeatable methods that reduce development time, but the diversity of modern biologics means one standard approach cannot cover every molecule. Suppliers able to offer engineered affinity tools, development support, and scalable manufacturing pathways are likely to become more important as pipelines diversify.
Navigo Pure’s next phase will be measured by how effectively it can expand catalogue and custom products while maintaining technical support for regulated bioprocessing. The leadership change signals the increasing commercial weight of purification technology in the industrialisation of modern biologics.
